Purchase Order 36C24526P0324
Award Date 3/24/26
Potential Completion Date 3/27/26
Potential Value $38K
Federal Agency
Awardee
Ultimate Awardee
NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Brooks, KY 40109, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Veterans Affairs, Veterans Integrated Service Network 5 (VISN 5) awarded a firm fixed-price purchase order to Theracom, L.L.C. for $38,097.52 for the supply of TAKHZYRO 150 MG, a specialized biologic pharmaceutical therapy. The contract was awarded on March 2, 2026, with an ultimate completion date of March 4, 2026, and no set-aside designation was utilized. Theracom, headquartered in Shepherdsville, Kentucky and operating from its Brooks, Kentucky facility, is a specialized...
- The Department of Veterans Affairs, Veterans Integrated Service Network 2 (VISN 2) awarded a $38,875.02 firm fixed-price purchase order to Theracom, L.L.C. on March 18, 2026 for the supply of TAKHZYRO 150MG/ML injection in 2ML syringe formulation. The contract, which will be completed by March 25, 2026, was awarded without a set-aside designation and will be performed at Theracom's location in Brooks, Kentucky. Theracom is a specialty pharmaceutical distributor headquartered in Shepherdsville,...
- The Department of Veterans Affairs, Veterans Integrated Service Network 2 (VISN 2) awarded a firm fixed-price purchase order to Theracom, L.L.C. for TAKHZYRO 150MG/ML injection in 2ML syringe formulation on February 24, 2026. The contract has a ceiling value of $38,875.02 with an ultimate completion date of March 24, 2026. The award was made without a set-aside designation, reflecting full and open competition. Theracom, a Kentucky-based pharmaceutical specialty distributor headquartered in...
- Theracom, L.L.C., a child entity, has been awarded a firm fixed price purchase order by the Veterans Integrated Service Network 2 (VISN 2), a civilian component of the Department of Veterans Affairs, for the supply of TAKHZYRO 150MG. The contract, issued on December 1, 2025, carries a ceiling value of $75,478.12 and is scheduled for ultimate completion by December 30, 2025. The contract was awarded without a set-aside designation and will be performed in Brooks, Kentucky. TAKHZYRO...
- Theracom, L.L.C., a child entity, was awarded a firm fixed-price purchase order by Veterans Integrated Service Network 2 on October 20, 2025, for the supply of TAKHZYRO (pegtanercept) 150MG/ML injection in a 2ML syringe formulation. This is a pharmaceutical supply contract with a ceiling value of approximately $37.7K, with an ultimate completion date of November 20, 2025. The contract was awarded without a set-aside designation, and the place of performance is listed as Brooks, Kentucky. This...
- On January 15, 2026, the Department of Veterans Affairs, Veterans Integrated Service Network 5, awarded a delivery order valued at $38,097.52 to Takeda Pharmaceuticals America Inc. for TAKHZYRO 150 MG, a specialized pharmaceutical product used to treat rare genetic disorders. This firm fixed-price delivery order, with an ultimate completion date of January 20, 2026, represents a child contract under the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB) and does not utilize a set-aside...
- The Department of Veterans Affairs (VA) Veterans Health Administration awarded a firm fixed-price delivery order to Takeda Pharmaceuticals America Inc. under the company's Pharmaceuticals and Drugs GSA Schedule contract. The $36,890.40 order is for the specialty pharmaceutical product TAKHZYRO 150MG ML SYRINGE 2ML PER SYRINGE, which is used to treat hereditary angioedema. The delivery order has an April 2024 completion date and will support patient care programs across the VA's Veterans...
- The Department of Veterans Affairs Veterans Health Administration awarded Takeda Pharmaceuticals America Inc. a $36,101.68 firm fixed price delivery order for two packages of TAKHZYRO 150MG/ML prefilled syringes. Takeda Pharmaceuticals America Inc. will deliver the packages of the hereditary angioedema preventative medication to a location in Lexington, Massachusetts by November 1, 2023 to support VHA programs. The award was issued against Takeda Pharmaceutical Company Limited's...
- This federal contract award was issued by the Department of Veterans Affairs (VA) to Takeda Pharmaceuticals America Inc., a subsidiary of the global biopharmaceutical company Takeda Pharmaceutical Company Limited. The contract is a delivery order under Takeda's General Services Administration (GSA) Pharmaceuticals and Drugs Schedule contract, with a ceiling value of $55,335.60 and a completion date of June 28, 2024. The contract is for the supply of TAKHZYRO, a specialty pharmaceutical product...
- The Department of Veterans Affairs Veterans Health Administration awarded Takeda Pharmaceuticals America Inc. a $36,101.68 firm fixed price delivery order against the company's GSA Schedule contract for Pharmaceuticals and Drugs. The delivery order is for TAKHZYRO 150MG/ML SYRINGE 2ML SYRINGE (2) to be supplied to Veterans Integrated Service Network 9, with performance taking place in Lexington, Massachusetts from September 6-7, 2023. As the prime contractor, Takeda Pharmaceuticals America...